

# Financial Tear Sheet

## Corporate Profile

We are a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, [Subsys®](#), which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules.

In March 2012, we launched [Subsys®](#), our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in adult opioid-tolerant patients, through our cost-efficient commercial organization of approximately 250 sales professionals.

Since late 2014, [Subsys®](#) has been the most prescribed transmucosal immediate-release fentanyl, or TIRF, product with 48% market share on a prescription basis, according to IMS.

In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS, through our exclusive distributor, a leading generic pharmaceutical company.

Our lead product candidate is [Dronabinol Oral Solution](#), a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market [Dronabinol Oral Solution](#) and any other future supportive care products, if approved, through our commercial organization.

Please see [full prescribing information](#) for [Subsys®](#) including the boxed warning.

## SEC FILINGS

| FILING DATE | FORM |
|-------------|------|
| 08/17/17    | 4    |
| 08/16/17    | 3    |
| 08/14/17    | 4    |
| 08/10/17    | 4    |

### INSYS Therapeutics, Inc.

Attn: Secretary of the Board of Directors  
1333 South Spectrum Blvd, Suite 100  
Chandler, AZ 85286  
Phone: (602) 910-2617  
Fax: (602) 910-2627

## Stock Information

| INSY (COMMON STOCK)              |                       |
|----------------------------------|-----------------------|
| Exchange                         | NASDAQ GS (US Dollar) |
| Price                            | \$7.61                |
| Change (%)                       | ▲ 0.02 (0.26%)        |
| Volume                           | 89,469                |
| 52 Week Low                      | \$7.28                |
| Market Cap                       | \$553,221,484         |
| Rolling EPS                      | -0.21                 |
| PE Ratio                         | 0                     |
| Shares Outstanding               | 72,696,647            |
| Data as of 10/20/17 4:00 p.m. ET |                       |



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Recent News

| DATE     | TITLE   |
|----------|---|
| 10/19/17 | INSYS Therapeutics to Report Third Quarter 2017 Results on Nov. 2   |
| 10/09/17 | INSYS Therapeutics, Inc. to Participate in Oppenheimer Specialty Pharma Summit                                |
| 10/09/17 | INSYS Therapeutics Extends 'Compassionate Use' Studies of Cannabidiol (CBD) for Refractory Pediatric Epilepsy |

## Upcoming Events

| DATE                        | TITLE   |
|-----------------------------|---|
| 11/02/17<br>8:30<br>a.m. ET | Q3 2017 Insys Therapeutics Inc Earnings Conference Call |

## Ownership Profile

| SHAREHOLDERS |         |              |       |            |
|--------------|---------|--------------|-------|------------|
|              | Holders | Value (\$MM) | % O/S | Shares     |
| Institution  | 183     | 765.39       | 95.3  | 69,274,304 |
| Mutual Fund  | 187     | 98.45        | 13.8  | 10,034,845 |
| Insider *    | 9       | 2.23         | 0.3   | 194,888    |

\*Insider values reflect direct beneficial ownership.

| TOP HOLDERS                                 |             |       |              |             |
|---|-------------|-------|--------------|-------------|
|   | Shares Held | % O/S | Share Change | Filing Date |
| John N. Kapoor Trust                        | 42,430,310  | 58.4  | 55,700       | 03/15/17    |
| OrbiMed Advisors, LLC                       | 6,171,440   | 8.5   | 100,000      | 06/30/17    |
| Kapoor Children's 1992 Trust                | 4,557,950   | 6.3   | 0            | 03/15/17    |
| BlackRock Institutional Trust Company, N.A. | 2,451,684   | 3.4   | 26,105       | 06/30/17    |
| The Vanguard Group, Inc.                    | 2,333,254   | 3.2   | -17,853      | 06/30/17    |
| Kapoor (John N)                             | 1,180,368   | 1.6   | 0            | 03/15/17    |
| APG Asset Management                        | 1,114,542   | 1.5   | 279,298      | 03/31/17    |
| Folger Hill Asset Management LLC            | 780,283     | 1.1   | -225,978     | 06/30/17    |
| Horizons ETFs Management (Canada) Inc.      | 699,483     | 1.0   | 71,307       | 08/31/17    |
| Mirae Asset Global Investments (USA) LLC    | 634,001     | 0.9   | 634,001      | 06/30/17    |